SCHEMBL23328190

SCHEMBL23328190

Cc1cccc(F)c1-c1cc(N[C@@H]2CCCN(C(=O)OC(C)(C)C)C2)c2cc(N)ncc2c1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 3/20 0.43
ABL1 P00519 1/20 0.42
PARP1 P09874 1/20 0.42
PIM1 P11309 2/20 0.42
PIM2 Q9P1W9 2/20 0.42
ALOX5AP P20292 4/20 0.41
FEN1 P39748 4/20 0.41
PIK3CD O00329 1/20 0.40
HDAC4 P56524 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
PIK3CA P42336 1/20 0.39
GABRA5 P31644 1/20 0.39
PRKCZ Q05513 1/20 0.38
EGFR P00533 2/20 0.38
BTK Q06187 2/20 0.38
ITK Q08881 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC2 Q92769 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25044333 1.00 USP30 (0.43) USP30ABL1PARP1PIM1PIM2
SCHEMBL25043248 0.98 ABL1 (0.42) USP30ABL1PARP1PIM1PIM2
SCHEMBL30175731 0.98 ABL1 (0.42) USP30ABL1PARP1PIM1PIM2
SCHEMBL25044183 0.98 ABL1 (0.42) USP30ABL1PARP1PIM1PIM2
SCHEMBL25043928 0.95 PIK3CD (0.44) USP30ABL1PARP1PIM1PIM2
SCHEMBL25044178 0.95 PIK3CD (0.44) USP30ABL1PARP1PIM1PIM2
SCHEMBL25043929 0.92 ABL1 (0.42) USP30ABL1PIM1PIM2ALOX5AP
SCHEMBL23301537 0.91 BTK (0.44) ABL1PIM1PIM2ALOX5APFEN1
SCHEMBL29897394 0.91 BTK (0.44) ABL1PIM1PIM2ALOX5APFEN1
SCHEMBL25043962 0.88 IRAK1 (0.47) ABL1ALOX5APFEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230045929-A1 ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-02-16 US disclosed
WO-2021084265-A1 ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230045929-A1 ISOQUINOLINE DERIVATIVES AS SIK2 INHIBITORS SIK2, SIK3, SIK1 USP30 3415/4885ABL1 444/4885PARP1 1936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.